MorphoSys

Novartis Meets Offer Conditions To Buy MorphoSys In EUR 68/shr Cash Deal
NASDAQ
Fri, 05/17/24 - 11:24 am
Novartis
MorphoSys
M&A
Novartis may have bought MorphoSys, but it really only had eyes for BET inhibitor pelabresib: filing
Fierce Biotech
Fri, 04/12/24 - 11:23 am
Novartis
MorphoSys
pelabresib
myelofibrosis
M&A
BET inhibitor
Novartis begins tender offer for cancer-focused MorphoSys
Reuters
Thu, 04/11/24 - 11:54 am
Novartis
M&A
cancer
MorphoSys
7 Billion-Dollar Oncology M&As from Q1
BioSpace
Wed, 04/10/24 - 11:24 am
oncology
M&A
AbbVie
Immunogen
Bristol Myers Squibb
Mirati Therapeutics
RayzeBio
Novartis
MorphoSys
AstraZeneca
Fusion Pharmaceuticals
JNJ
Ambrx
Gracell
Fierce Biotech's Quarterly IPO and M&A Roundup: Q1'24
Fierce Biotech
Wed, 04/3/24 - 11:36 am
biotech
M&A
IPOs
CG Oncology
Kyverna Therapeutics
Contineum Therapeutics
Boundless Bio
CymaBay Therapeutics
Gilead Sciences
MorphoSys
Novartis
Fusion Pharmaceuticals
AstraZeneca
Ambryx
JNJ
Inhibrix
Aventis
Novartis in the lead to acquire cancer drug developer MorphoSys-sources
NASDAQ.com/Reuters
Mon, 02/5/24 - 11:28 am
Novartis
M&A
MorphoSys
cancer
MorphoSys’ pelabresib meets endpoints in Phase III myelofibrosis trial
Clinical Trials Arena
Tue, 11/21/23 - 11:55 am
MorphoSys
clinical trials
pelabresib
myelofibrosis
MorphoSys Cuts Pre-Clinical Programs, 17% of Staff
BioSpace
Thu, 03/2/23 - 10:46 pm
MorphoSys
layoffs
Autoimmune drug biotech HI-Bio unveils $120M to root out cellular drivers of disease
MedCity News
Tue, 11/1/22 - 10:55 am
Human Immunology Bioscience
autoimmune disease
R&D
MorphoSys
kidney disease
MorphoSys Adds HIBio to Busy Collaboration Week
BioSpace
Wed, 06/15/22 - 11:03 am
MorphoSys
HIBio
Pfizer
Incyte
Opportunities arise for once-spurned partners
EP Vantage
Fri, 05/13/22 - 10:34 am
Pfizer
Biohaven
licensing
M&A
Aurinia
Bristol Myers Squibb
AbbVie
Alector
Arcus Biosciences
Biogen
Blueprint Medicines
CureVac
Gilead Sciences
GSK
Incyte
MorphoSys
Roche
Nestle
SAGE Therapeutics
Sarepta Therapeutics
Seres Therapeutics
Syndax
MorphoSys cuts R&D from Constellation deal to focus on clinical-stage cancer drugs
MedCity News
Fri, 03/11/22 - 10:42 am
MorphoSys
drug discovery
R&D
Constellation Pharmaceuticals
M&A
In a quiet year for takeouts, who was buying?
EP Vantage
Fri, 01/28/22 - 09:54 am
M&A
Jazz Pharmaceuticals
Horizon Pharma
MorphoSys
BioMarin stands tall with first approved drug for rare disease that causes dwarfism
MedCity News
Sat, 08/28/21 - 08:57 pm
Biomarin
Europe
achondroplasia
dwarfism
Incyte
MorphoSys
Biotech M&A tracker: After hitting new heights, deals have slowed down. Here are the latest.
BioPharma Dive
Tue, 08/10/21 - 11:12 pm
M&A
Bayer
Sanofi
Amgen
uniQure
MorphoSys
Xeris Pharmaceuticals
Relay Therapeutics
Merck
Beam Therapeutics
Jazz Pharmaceuticals
Biopharma takeovers dry up
EP Vantage
Mon, 07/5/21 - 09:50 pm
M&A
MorphoSys
Constellation Pharmaceuticals
Sanofi
Tidal Therapeutics
uniQure
Corlieve Therapeutics
Strongbridge Biopharma
Xerix Pharmaceuticals
Novellus Therapeutics
Brooklyn Immunotherapeutics
Morphosys to buy Constellation in $1.7B deal, aided by unusual funding
BioPharma Dive
Wed, 06/2/21 - 12:10 pm
MorphoSys
M&A
Constellation Pharmaceuticals
OptumRx's 3 recently approved drugs to watch
Beckers Hospital Review
Tue, 09/22/20 - 10:15 pm
FDA
Kite Pharma
Tecartus
Novartis
Kesimpta
MorphoSys
Monjuvi
OptumRx
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
MedCity News
Mon, 08/3/20 - 10:14 am
FDA
Monjuvi
CAR-T
MorphoSys
Incyte
diffuse large B-cell lymphoma
Morphosys’ off-the-shelf rival to CAR-T approaches finish line with a speedy review
Endpoints
Mon, 03/2/20 - 09:37 am
MorphoSys
Gilead Sciences
Novartis
CAR-T
tafasitamab
DLBCL

Pages